Book contents
- Frontmatter
- Contents
- List of Contributors
- 1 Introduction
- 2 Mechanistic basis for the therapeutic effectiveness of botulinum toxin A on over-active cholinergic nerves
- 3 Botulinum toxin: from menace to medicine
- 4 Botulinum toxin: primary and secondary resistance
- 5 Introduction to botulinum toxin in clinical practice
- 6 Cervical dystonia
- 7 The use of botulinum toxin in otolaryngology
- 8 Spasticity
- 9 Hyperhidrosis
- 10 Hypersalivation
- 11 Botulinum toxin type A for the prophylactic treatment of primary headache disorders
- 12 Botulinum toxin in the management of back and neck pain
- 13 Clinical uses of botulinum toxin
- 14 Bladder and bowel indications
- 15 Cosmetic uses of botulinum toxin A
- 16 Other clinical neurological uses of botulinum toxin
- Index
- Plate section
- References
11 - Botulinum toxin type A for the prophylactic treatment of primary headache disorders
Published online by Cambridge University Press: 02 December 2009
Book contents
- Frontmatter
- Contents
- List of Contributors
- 1 Introduction
- 2 Mechanistic basis for the therapeutic effectiveness of botulinum toxin A on over-active cholinergic nerves
- 3 Botulinum toxin: from menace to medicine
- 4 Botulinum toxin: primary and secondary resistance
- 5 Introduction to botulinum toxin in clinical practice
- 6 Cervical dystonia
- 7 The use of botulinum toxin in otolaryngology
- 8 Spasticity
- 9 Hyperhidrosis
- 10 Hypersalivation
- 11 Botulinum toxin type A for the prophylactic treatment of primary headache disorders
- 12 Botulinum toxin in the management of back and neck pain
- 13 Clinical uses of botulinum toxin
- 14 Bladder and bowel indications
- 15 Cosmetic uses of botulinum toxin A
- 16 Other clinical neurological uses of botulinum toxin
- Index
- Plate section
- References
Summary
Introduction
Migraine is a chronic neurovascular disorder that afflicts 8–15 per cent of the world's population and is the most common primary headache disorder in clinical practice. In the United States there are an estimated 28 million migraine sufferers, with women being affected three times as often as men. It is characterized by severe headaches and is often associated with nausea, vomiting, heightened sensitivity to sound and light, and focal (paresthesias, visual scintillations) and global (impaired concentration) neurological dysfunction. Migraine is considered to be one of the top 20 causes of disability due to chronic diseases, and severe migraine has been judged by the World Health Organization to be as disabling as quadriplegia, psychosis, and dementia.
Most sufferers are in their most socially active and productive years (25–55). Not only is migraine painful and disabling for the sufferer, but it exerts a significant economic burden on society. It causes 112 million bedridden days each year and costs $14 billion in reduced productivity and missed workdays. The economic burden of migraine is comparable with that of diabetes and higher than that of asthma.
Even among migraineurs who consult a physician, many are not satisfied with their therapy and report that prescribed medications are not always optimal. Triptan medications, the most effective acute therapy for migraine attacks, are only effective in improving the pain and associated migraine symptoms, such as photophobia and nausea, in up to two thirds of patients.
- Type
- Chapter
- Information
- Clinical Uses of Botulinum Toxins , pp. 229 - 242Publisher: Cambridge University PressPrint publication year: 2007
References
, , , and (2001). Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 41, 646–57.CrossRefGoogle ScholarPubMed
, and (2000). The global burden of disease study: implications for neurology. Arch. Neurol., 57, 418–20.CrossRefGoogle ScholarPubMed
, , , and (1999). Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med., 159, 813–18.CrossRefGoogle ScholarPubMed
(1996). Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo, 10, 255–9.Google ScholarPubMed
, and (1992). An economic evaluation of asthma in the United States. N. Engl. J. Med., 326, 862–6.CrossRefGoogle ScholarPubMed
, and (2002). Migraine: current understanding and treatment. N. Engl. J. Med., 346, 257–70.CrossRefGoogle ScholarPubMed
, , and (2003). Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain, 106, 81–9.CrossRefGoogle ScholarPubMed
, , and (1998). Prevalence of frequent headache in a population sample. Headache, 38, 497–506.CrossRefGoogle Scholar
(2000). Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology, 55, 754–62.CrossRefGoogle Scholar
, , et al. (2002). Migraine in the United States: epidemiology and patterns of health care use. Neurology, 58, 885–94.CrossRefGoogle ScholarPubMed
(2003). Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache, 43(Suppl. 1), S16–S24.CrossRefGoogle ScholarPubMed
, , . and (2004). Noncosmetic uses of botulinum toxin. Dermatol. Clin., 22, 187–95.CrossRefGoogle ScholarPubMed
(2003). Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache, 43(Suppl. 1), 9–15.CrossRefGoogle ScholarPubMed
, , . and (2004). Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain, 107, 125–33.CrossRefGoogle ScholarPubMed
and (2004). Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache, 44, 35–42; discussion 42–3.CrossRefGoogle ScholarPubMed
, , , . and (2004). Botulinum toxin type A blocks sensitization of neurons in the trigeminal nucleus caudalis. Cephalalgia, 24, 781.Google Scholar
. and (2004). Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol., 55, 27–36.CrossRefGoogle Scholar
, , , et al. (2000). Botulinum toxin type A as a migraine preventive treatment. Headache, 40, 445–50.CrossRefGoogle ScholarPubMed
. and (2003). Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J. Headache Pain, 4, 146–51.CrossRefGoogle Scholar
, , . and (2004). Botulinum neurotoxin type A in the preventative treatment of refractory headache: a review of 100 consecutive cases. Headache, 44, 794–800.CrossRefGoogle Scholar
(2004). Botulinum toxin type A (BOTOX®) in the treatment of migraine and other headaches. Expert Rev. Neurotherapeutics, 41, 27–31.CrossRefGoogle Scholar
(2003). Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache, 43, 853–60.CrossRefGoogle ScholarPubMed
Brin, M. F., Binder, W. J., Blitzer, A, Schenrock, L. and Pogoda, J. M. (2002). Botulinum toxin type A for pain and headache. In , and , eds., Scientific and Therapeutic Aspects of Botulinum Toxin. New York: Lippincott Williams & Wilkins, pp. 233–50.Google Scholar
, , et al. (2004). Botulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo-controlled study. Cephalalgia, 24, 838–43.CrossRefGoogle Scholar
, , . and (1999). Prevalence of frequent headache in a population sample. Headache, 38(7), 497–506.CrossRefGoogle Scholar
, , . and (1999). Epidemiology of chronic daily headache in the general population. Headache, 39(3), 190–6.CrossRefGoogle ScholarPubMed
, , , , , et al. (2000). Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up. Neurology, 54(2), 314–19.CrossRefGoogle ScholarPubMed
, . and (2001). Epidemiology of chronic daily headache. Curr. Pain Headache Rep., 5(6), 529–36.CrossRefGoogle ScholarPubMed
, , , , , et al. (2003). Prevalence and description of chronic daily headache in the general population in France. Pain, 102(1–2), 143–9.CrossRefGoogle ScholarPubMed
, , , , . and et al. (2003). Quality of life and disability in primary chronic daily headaches. Neurol. Sci., 24(Suppl. 2), S97–S100.Google ScholarPubMed
, , . and (2002). Quality of life in chronic daily headache: a study in a general population. Neurology, 58(7), 1062–5.CrossRefGoogle Scholar
, , , (2001). Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain, 89(2–3), 285–92.CrossRefGoogle ScholarPubMed
, . and (1982). Transformation of episodic migraine into daily headache: analysis of factors. Headache, 22, 66–8.CrossRefGoogle Scholar
, , and (1994). Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache, 34, 497–502.CrossRefGoogle ScholarPubMed
, , and (2002). Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache, 42, 510–14.CrossRefGoogle ScholarPubMed
, , for the Australian Gabapentin Chronic Daily Headache Group. (2003). Neurology, 61, 1753–9.CrossRef
, , , and (2002). Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache, 42, 470–82.CrossRefGoogle ScholarPubMed
, , , , . and (2003). Topiramate in the treatment of chronic migraine. Cephalalgia, 23, 820–4.CrossRefGoogle ScholarPubMed
, and (2004). Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia, 24, 60–5.CrossRefGoogle ScholarPubMed
(2003). Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache, 43, 25–9.CrossRefGoogle ScholarPubMed
, , and (1996). Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve, 19, 488–95.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
, , et al. (2004). Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia, 24, 675–80.CrossRefGoogle ScholarPubMed
and , BoNTTH Study Group. (2004). Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain, 109, 110–14.CrossRefGoogle ScholarPubMed
(1997). Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve, 20 (Suppl. 6), S146–S168.3.0.CO;2-4>CrossRefGoogle Scholar